A Trial to Evaluate the Efficacy and Safety of EFLA400 Korea Red Ginseng Extract on Sexual Function in Men With Erectile Dysfunction

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified December 2010 by Chonbuk National University Hospital.
Recruitment status was: Enrolling by invitation

Sponsor:

Information provided by:

Chonbuk National University Hospital

ClinicalTrials.gov Identifier:

NCT01479426

First received: November 16, 2011

Last updated: November 23, 2011

Last verified: December 2010

History of Changes

Purpose

Korea red ginseng has been used in maintaining vitality throughout the globally and metabolism and actions on neurologic, cardiovascular, and endocrinologic system are studied. KRG has been used in various ailment, and to prove its efficacy for erectile dysfunction an international study on contries other than Korean was performed. In the present study, subjects with borderline organic and psychogenic erectile dysfunction will be included. KRG will be give daily, and placebo will be give as control. Outcomes including libido, erection, sexual activity, and sexual satisfaction will be measured.

Condition	Intervention	Phase
Healthy Subjects(Only Men)	Dietary Supplement: EFLA400 Dietary Supplement: Placebo	Phase 2 Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Prevention
Official Title:	Efficacy and Safety of EFLA400 Korea Red Ginseng Extract on Erectile Dysfunction

Resource links provided by NLM:

MedlinePlus related topics: Erectile Dysfunction

U.S. FDA Resources

Further study details as provided by Chonbuk National University Hospital:

Primary Outcome Measures:

IIEF-5 score [ Time Frame: Change from baseline in IIEF-5 score at 12 weeks ]

Secondary Outcome Measures:

MSHQ [ Time Frame: Change from baseline in MSHQ score at 12 weeks ]
GEAQ [ Time Frame: Change from baseline in GEAQ score at 12 weeks ]
uroflowmetry(max flow rate) [ Time Frame: Change from baseline in uroflowmetry at 12 weeks ]


Estimated Enrollment:	80
Study Start Date:	December 2010
Estimated Study Completion Date:	July 2012
Estimated Primary Completion Date:	March 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: EFLA400(960mg)	Dietary Supplement: EFLA400 EFLA400(960mg/day)for 12 weeks Other Name: EFLA400 Korean red ginseng
Placebo Comparator: Placebo(960mg)	Dietary Supplement: Placebo Placebo(960mg/day) for 12 weeks

Detailed Description:

Among the three main lines of therapy for erectile dysfunction (ED), that is, oral therapy, self-injection therapy and penile prosthesis implantation, the first line therapy is always the first option. Despite the successful advent of sildenafil, the first effective oral agent for ED, further development of new drugs and phytochemical studies of widely known herbal plants are desirable. Furthermore, there seems to be a large population that prefers to use phytotherapies rather than pharmaceutical drugs for their health. Korean red ginseng, a phytotherapy plants, used frequently for ED. Ginseng is one of the most popular herbs in both Eastern and Western countries. It is known as a traditional Asian medicine for stimulation of sexual function and studies have shown the effects of ginseng on relaxation of penile corpus cavernous smooth muscle in many studies. In the present study, the investigators will be determined the real role of Korean red ginseng in the treatment of ED.

Eligibility


Ages Eligible for Study:	35 Years to 65 Years (Adult)
Sexes Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

aged 35-65 years
IIEF-5 scores between 13 and 21

Exclusion Criteria:

they had other neurologic or psychiatric disorder
significant hepatic or renal function impairment (hepatic enzymes >1.5 times the upper limit of normal and/or serum creatinine >1.8 mg per 100 ml)
hypertension (>170/110 mm Hg), hypotension (<90/50 mm Hg) or significant cardiovascular disease (unstable angina, coronary artery disease, myocardial infarction or myocardial revascularization).
Peyronie's disease

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01479426

Locations


Korea, Republic of
Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
Jeonju, Jeollabuk-do, Korea, Republic of, 560-822

Sponsors and Collaborators

Chonbuk National University Hospital

Investigators


Principal Investigator:	Jong-Kwan Park, MD	Chonbuk National University Hospital

More Information


ClinicalTrials.gov Identifier:	NCT01479426 History of Changes
Other Study ID Numbers:	LOTTE-MS-EFLA400
Study First Received:	November 16, 2011
Last Updated:	November 23, 2011

Keywords provided by Chonbuk National University Hospital:


Erectile dysfunction Korean Red Ginseng IIEF MSHQ

Additional relevant MeSH terms:


Erectile Dysfunction Sexual Dysfunction, Physiological Genital Diseases, Male Sexual Dysfunctions, Psychological Mental Disorders

ClinicalTrials.gov processed this record on September 20, 2017

To Top